Loading…
Employees: 226
Size AVITA Medical (RCEL) is a United States Health Care company (Medical Specialties) with a market value of $513M, the 2679th largest of 3,117 United States companies the cockpit tracks. Shares closed at $16.59 on 6 Nov 2026.
Performance Over six months the shares gained 303.6%, against -13.9% for the median peer and -1.1% for the United States market (cap-weighted) — highest of 21 in its peer set.
Growth Revenue grew 1.0% over the last twelve months (peer median +1.7%); the operating margin is -46.6% (peer median 2.4%).
Valuation It trades at 7.3× enterprise value to sales against a peer median of 4.5× (5th most expensive of 18).
Backlog Backlog (remaining performance obligations) was $300,000 at 30 Sep 2026, flat on a year earlier — 0.0 years of trailing revenue. Backlog detail →
Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $75.6M | $71.6M | $64.3M | $50.1M | $34.4M |
| Revenue growth | — | +11% | +28% | +46% | — |
| Gross profit | $61.7M | $58.8M | $55.2M | $42.4M | $28.4M |
| EBITDA | -$32.7M | -$39.6M | -$55.4M | -$121M | -$29.2M |
| Net income | -$43.1M | -$48.6M | -$61.8M | -$35.4M | -$26.7M |
| Free cash flow | -$25.1M | -$32.2M | -$58.1M | -$39.4M | -$19.5M |
| Capital expenditure | $492,547 | $1.10M | $9.33M | $1.45M | $525,000 |
| Total debt | $48.5M | $46.0M | $46.0M | $42.4M | $918,000 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | RCEL | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +24.5% | -4.3% | 2nd highest of 21 |
| 6-month return | +303.6% | -13.9% | highest of 21 |
| Distance from 52-week high | -8.2% | -40.2% | 2nd highest of 21 |
| Revenue growth (TTM) | +1.0% | +1.7% | 10th lowest of 21 |
| Operating margin | -46.6% | 2.4% | 3rd lowest of 21 |
| EV / Sales | 7.3× | 4.5× | 5th most expensive of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| AVITA Medical RCEL | United States | $513M | +304% | +1% | -47% | 7.3× | n/a | n/a |
| Delcath Systems DCTH | United States | $518M | +30% | +36% | -2% | 4.5× | 10.1% | +120.2% |
| Guangdong Biolight Meditech 300246.SZ | China | $519M | -23% | +4% | -9% | 3.4× | 14.8% | -4.7% |
| Hangzhou Alltest Biotech 688606.SS | China | $521M | -15% | 0% | 13% | 1.6× | -3.9% | -4.3% |
| Wuhan Easy Diagnosis Biomedicine 002932.SZ | China | $499M | -14% | -9% | -51% | n/a | n/a | n/a |
| Jin Medical International ZJYL | United States | $532M | +53% | -14% | 2% | 26.5× | n/a | n/a |
| Revenio REG1V.HE | Finland | $494M | -22% | +16% | 14% | 5.5× | 19.3% | +12.4% |
| AngioDynamics ANGO | United States | $493M | +5% | +8% | -6% | 1.4× | n/a | n/a |
| medmix MEDX.SW | Switzerland | $537M | +24% | -7% | 6% | 1.5× | 5.0% | +5.0% |
| Zhejiang Starry Pharmaceutical 603520.SS | China | $537M | -32% | +9% | 3% | 2.3× | n/a | n/a |
| Assure Tech (Hangzhou) 688075.SS | China | $538M | -25% | -21% | -7% | n/a | n/a | n/a |
| WELL LEAD MEDICAL 603309.SS | China | $486M | -19% | +1% | 15% | 2.0× | -5.6% | +7.7% |
| Medprin Regenerative Medical Technologies 301033.SZ | China | $542M | -3% | +23% | 31% | 8.0× | 6.3% | +24.4% |
| CellaVision CEVI.ST | Sweden | $485M | +68% | +2% | 23% | 6.0× | 6.5% | +10.0% |
| MiMedx MDXG | United States | $483M | -8% | -23% | -8% | 1.2× | 11.5% | +11.0% |
| Beijing Leadman Biochemistry 300289.SZ | China | $483M | -11% | -6% | -12% | 7.5× | 35.5% | -6.9% |
| Nanjing Vishee Medical Technology 688580.SS | China | $550M | -40% | +7% | 24% | 6.0× | 22.3% | +4.2% |
| China Isotope & Radiation 1763.HK | Hong Kong | $478M | -38% | -5% | 13% | n/a | n/a | n/a |
| Shofu 7979.T | Japan | $475M | +27% | +7% | 14% | 1.6× | n/a | n/a |
| Anteris Technologies Global AVR | United States | $555M | -14% | -10% | -4,738% | 134.2× | n/a | n/a |
| Sight Sciences SGHT | United States | $555M | -14% | +9% | -33% | 6.2× | n/a | n/a |
AVITA Medical reported $300,000 of remaining performance obligations at 30 Sep 2026, flat from a year earlier and flat from the previous quarter. That is 0.0 years of trailing revenue already under contract. Book-to-bill last quarter: 1.00.